Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive.

Slides:



Advertisements
Similar presentations
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study by Martin Schrappe, Maria.
Advertisements

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Reduced tumor load in peripheral blood after treatment with G-CSF and chemotherapy in children with tumors of the Ewing sarcoma family but not neuroblastoma.
Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial.
Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence by Bettina R. Bonn, Marius Rohde,
Rearranged Ig Heavy Chain DNA Is Detectable in Cell-Free Blood Samples of Patients With B-Cell Neoplasia by N. Frickhofen, E. Müller, M. Sandherr, T. Binder,
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Nonmyeloablative conditioning for relapsed follicular lymphoma
Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors  Mitchell S. Cairo,
Short-pulse B–non-Hodgkin lymphoma–type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster.
Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
Treatment of Patients with Adult T Cell Leukemia/Lymphoma with Cord Blood Transplantation: A Japanese Nationwide Retrospective Survey  Koji Kato, Ilseung.
Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma
New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years by Pietro Sodani, David Gaziev, Paola Polchi,
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML by Nona Shayegi, Michael Kramer,
Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.
by Michael F. Leahy, and J. Harvey Turner
Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index by Chor-Sang Chim, Shing-Yan.
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male.
by George Z. Rassidakis, Mauricio P. Oyarzo, and L. Jeffrey Medeiros
The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.
Yang et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008;112(3):805–813. Blood Volume 114(14): October.
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:
Role of primacy of birth in HLA-identical sibling transplantation
Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia  Vivian.
Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.
Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study 
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.
Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma  Mark Korthals, Nina Sehnke, Ralf Kronenwett,
John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J
Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation  Herbert Pichler,
New-Onset Lymphopenia Assessed during Routine Follow-up Is a Risk Factor for Relapse Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation.
Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation 
Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System  Paul D. Harker-Murray,
Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation  Willis H. Navarro, Fausto R.
Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-
Improved Outcomes after Autologous Bone Marrow Transplantation for Children with Relapsed or Refractory Hodgkin Lymphoma: Twenty Years Experience at a.
The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age  Lujia Dong,
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.
C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.
Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation 
Sara C. Meyer, Alix O’Meara, Andreas S. Buser, André Tichelli, Jakob R
Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma  Ivan Aksentijevich,
A: Incidences of all-cause mortality, coronary artery events, and cerebrovascular events by quartiles of baPWV during the follow-up period. A: Incidences.
Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.
Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma (n=63). Kaplan-Meier estimates of event-free survival in children with.
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning for Adult T Cell Leukemia/Lymphoma: Impact of Antithymocyte Globulin.
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders  Martin Benesch, MD, H. Joachim.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.
Balancing bleeding in brain metastases
Cold agglutinin disease
Outcomes in patients with PTCL
Presentation transcript:

Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive anaplastic large-cell lymphoma by Christine Damm-Welk, Kerstin Busch, Birgit Burkhardt, Jutta Schieferstein, Susanne Viehmann, Ilske Oschlies, Wolfram Klapper, Martin Zimmermann, Jochen Harbott, Alfred Reiter, and Willi Woessmann Blood Volume 110(2):670-677 July 15, 2007 ©2007 by American Society of Hematology

Sensitivity of the qualitative RT-PCR for NPM-ALK. Sensitivity of the qualitative RT-PCR for NPM-ALK. NPM-ALK–positive Karpas 299 cells were diluted in DG 75 Burkitt lymphoma cells. Christine Damm-Welk et al. Blood 2007;110:670-677 ©2007 by American Society of Hematology

Comparison of quantitative NPM-ALK PCR results between bone marrow and peripheral blood. Comparison of quantitative NPM-ALK PCR results between bone marrow and peripheral blood. Number of NPM-ALK copies/104 copies ABL in bone marrow and peripheral blood of 19 patients with a positive RT-PCR in bone marrow and blood. Christine Damm-Welk et al. Blood 2007;110:670-677 ©2007 by American Society of Hematology

Cumulative incidence of relapse of 80 analyzed ALCL patients according to qualitative PCR results for NPM-ALK in bone marrow. Cumulative incidence of relapse of 80 analyzed ALCL patients according to qualitative PCR results for NPM-ALK in bone marrow. Christine Damm-Welk et al. Blood 2007;110:670-677 ©2007 by American Society of Hematology

Quantitative NPM-ALK PCR results in bone marrow according to the outcome of the ALCL patients. Quantitative NPM-ALK PCR results in bone marrow according to the outcome of the ALCL patients. Normalized NPM-ALK copy numbers (copies NPM-ALK/104 copies ABL) in bone marrow of the 74 patients with either a negative qualitative BM PCR (= 0 copies NPM-ALK) or a positive qualitative BM PCR using quantitative PCR results. TRM indicates treatment related mortality; sec mal, second malignancy. Christine Damm-Welk et al. Blood 2007;110:670-677 ©2007 by American Society of Hematology

Outcome of ALCL patients according to quantitative PCR results for NPM-ALK in bone marrow. Outcome of ALCL patients according to quantitative PCR results for NPM-ALK in bone marrow. (A) Cumulative incidence of relapse and Kaplan-Meier estimates of (B) event-free survival and (C) overall survival of the 74 patients with either a negative qualitative BM PCR or a positive qualitative BM PCR using quantitative PCR results and a NPM-ALK cutoff copy number of 10/104 copies ABL (NCN). Christine Damm-Welk et al. Blood 2007;110:670-677 ©2007 by American Society of Hematology